Although the IMpower150 [32], ORIENT-31 and ATTLAS/KCSG-LU19-04 [33] studies have unanimously confirmed that patients with EGFR-TKI-resistant NSCLC can benefit from the four-drug combination therapy of immune + platinum-containing double-drug chemotherapy + bevacizumab. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.